Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase NA 1Phase 3 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Prostatic Neoplasms 3Esophageal Squamous Cell Carcinoma 3Adenocarcinoma Of Esophagus 3Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Skin Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Esophageal Diseases 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1Barrett Esophagus 1Adenocarcinoma 1

Interventions

Cytarabine 197Azacitidine 143Cyclophosphamide 136fludarabine phosphate 112fludarabine 97Busulfan 96venetoclax 95Mycophenolic Acid 82Whole-Body Irradiation 81Tacrolimus 78Peripheral Blood Stem Cell Transplantation 78Decitabine 62Filgrastim 56Granulocyte Colony-Stimulating Factor 54Cyclosporine 53Melphalan 52Methotrexate 51Idarubicin 51Daunorubicin 49Antilymphocyte Serum 47Clofarabine 43Etoposide 41Thiotepa 35Gemtuzumab 34Mitoxantrone 32Stem Cell Transplantation 31CPX-351 27Specimen Handling 25Radiotherapy 25thymoglobulin 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Myeloid, Acute × Itraconazole × Clear all
NCT05048615 2023-01-25

Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML

Hospital Universitario Dr. Jose E. Gonzalez

Phase 2 Completed
15 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡